Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model

MLA

Darren R. Shafren, et al. “Combination of a Novel Oncolytic Immunotherapeutic Agent, CAVATAK (Coxsackievirus A21) and Immune-Checkpoint Blockade Significantly Reduces Tumor Growth and Improves Survival in an Immune Competent Mouse Melanoma Model.” Journal for ImmunoTherapy of Cancer, vol. 2, no. Suppl 3, p. P125. EBSCOhost, https://doi.org/10.1186/2051-1426-2-s3-p125. Accessed 4 Feb. 2025.

APA

Darren R. Shafren, Howard L. Kaufman, Min Quah, Gough G. Au, Robert H.I. Andtbacka, & Yvonne Wong. (n.d.). Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model. Journal for ImmunoTherapy of Cancer, 2(Suppl 3), P125. https://doi.org/10.1186/2051-1426-2-s3-p125

Chicago

Darren R. Shafren, Howard L. Kaufman, Min Quah, Gough G. Au, Robert H.I. Andtbacka, and Yvonne Wong. 2025. “Combination of a Novel Oncolytic Immunotherapeutic Agent, CAVATAK (Coxsackievirus A21) and Immune-Checkpoint Blockade Significantly Reduces Tumor Growth and Improves Survival in an Immune Competent Mouse Melanoma Model.” Journal for ImmunoTherapy of Cancer 2 (Suppl 3): P125. Accessed February 4. doi:10.1186/2051-1426-2-s3-p125.